Inomagen Therapeutics

Developing a non-viral gene therapy to treat the underlying mechanisms for Atrial Fibrillation.

In September 2025, Inomagen Therapeutics was awarded 2nd Place at the HRX Live 2025 Pitch Competition in Atlanta. Competing among ten standout innovators shaping the future of cardiovascular care, Inomagen was recognized for pioneering a non-viral gene therapy that targets the underlying mechanisms of atrial fibrillation.

Hosted by the Heart Rhythm Society, HRX brings together clinicians, engineers, entrepreneurs, and investors to reimagine patient care. It is a forum for bold thinkers in cardiac electrophysiology to spark the partnerships and breakthroughs that will define the next decade of cardiovascular innovation.

Inomagen Therapeutics Receives Award at HRX Live 2025

Inomagen Therapeutics Recognized as a top-ranked company at RESI Boston June 2025

At RESI Boston June 2025, Inomagen was awarded 2nd Prize Winner in Life Science Nation’s Innovator’s Pitch Challenge from among 53 presenting companies — a major recognition of our pioneering non-viral gene therapy to improve the treatment of atrial fibrillation.

Companies presented their technologies to panels of active investors — including early-stage investors, startup executives, and industry leaders — who voted for the most impressive companies based on pitch presentations, Q&A performance, and networking in the exhibit hall.

Breakthroughs in Atrial Fibrillation Treatment—Now Within Reach

On March 13, 2025, Inomagen hosted a private webinar unveiling our revolutionary approach to treating atrial fibrillation at the source—not just the symptoms. Led by Founder Dr. Rishi Arora, the event explored how our proprietary gene therapy targets the root cause of AFib through a single-dose, minimally invasive procedure.

Backed by over a decade of research and validated in multiple preclinical models, this breakthrough platform has the potential to transform care for millions—and unlock a new frontier for strategic partners and investors.

Watch the 8-minute highlights version of the webinar below.

About Inomagen

Atrial fibrillation is the most common sustained heart rhythm disorder and a growing epidemic in an aging population. Unfortunately, current therapies have proven ineffective for many patients as they do not address the underlying mechanisms of the disease.

At Inomagen, we are exclusively focused on discovering and developing transformative gene therapies to markedly improve the treatment of atrial fibrillation. Our scientific advancements have been the result of significant non-dilutive grant funding. The company has an exclusive license agreement with Northwestern University for a robust IP estate and has assembled a highly experienced team to bring our therapies to market.

Inomagen is located in Chicago’s Fulton Market as a portfolio member of Portal Innovations – a Biotech Incubator with an expansive space designed to provide best-in-class, fully equipped wet/dry lab and work space.

The Inomagen Team

Rishi Arora, MD

FOUNDER

Dr. Arora is a well-published physician-scientist and a key thought leader in atrial fibrillation. He is a practicing electrophysiologist, Chief of Cardiology at University of Chicago, and leads one of the foremost academic programs in AF; he has raised over $20M in NIH and AHA grants for his work on AF mechanisms.
Gerard Abate, MD

CHIEF MEDICAL OFFICER

Dr. Abate has a background as a clinical cardiologist and is well experienced in the healthcare industry. Over the past 30 years Dr. Abate has held numerous Pharma/Diagnostics leadership roles including Amarin Pharmaceuticals, Daiichi Sankyo, Atherotech, and as the Executive Director of Medical Affairs at Quest Diagnostics.
Eric Sandberg

CHIEF BUSINESS OFFICER

Eric has 30+ years of medical technology leadership experience at Guidant, Boston Scientific, Axogen and several start-up ventures, in roles that have included CEO, CBO, and CCO, and brings significant commercial experience in the cardiovascular space including cardiac rhythm management.
Robin Drassler

VP, BUSINESS DEVELOPMENT

Robin has over 25 years of commercial experience in medical devices including COO at Gardner Medical Instruments, VP Sales & Market Development at Attune Medical, and various sales and market development roles at Covidien (Medtronic).
Robert Moen, MD, Ph.D.

VP, RESEARCH & DEVELOPMENT

Dr. Moen brings over 30 years of experience in gene and cell therapy, having led clinical development and commercialization efforts at Genetic Therapy, Copernicus Therapeutics, and Baxter Healthcare. He has held senior leadership roles in clinical, regulatory, and quality, and helped bring multiple therapies from bench to clinic.
David A. Johnson

RESEARCH ENGINEER

With over 40 years of engineering and IT experience, Johnson has led multimillion-dollar projects and contributed to non-viral gene delivery systems at Northwestern University’s Feinberg School of Medicine. He specializes in building custom equipment for translational cardiac research.
Jim Hausserman, MD, MS

SENIOR PROJECT MANAGER

Dr. Hausserman is a physician-scientist with expertise in regulatory strategy and product development. He has led efforts securing FDA and CE approvals for medical devices and contributed to early-stage testing of novel ablation technologies. He holds a Master’s in Bacteriology and has experience in NIH-funded research.
Crystle J. Kelly, Ph.D.

PRECLINICAL PROGRAM MANAGER

Crystle Kelly is a neuroscientist and biotech leader with over 20 years of experience in preclinical program management and translational research. Her expertise spans electrophysiology, neuroplasticity, pharmacology, and small molecule development. She has coordinated cross-functional teams advancing therapies and diagnostic tools for brain cancer, chronic pain, PTSD, and cognitive disorders.